$320.42
0.99% today
Nasdaq, Feb 28, 04:48 pm CET
ISIN
US91307C1027
Symbol
UTHR

United Therapeutics Corporation Stock price

$323.62
-45.94 12.43% 1M
-25.61 7.33% 6M
-29.22 8.28% YTD
+96.87 42.72% 1Y
+157.42 94.72% 3Y
+222.83 221.08% 5Y
+168.57 108.72% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+4.73 1.48%
ISIN
US91307C1027
Symbol
UTHR
Sector
Industry

Key metrics

Market capitalization $14.45b
Enterprise Value $11.48b
P/E (TTM) P/E ratio 13.16
EV/FCF (TTM) EV/FCF 10.65
EV/Sales (TTM) EV/Sales 3.99
P/S ratio (TTM) P/S ratio 5.02
P/B ratio (TTM) P/B ratio 2.25
Revenue growth (TTM) Revenue growth 23.63%
Revenue (TTM) Revenue $2.88b
EBIT (operating result TTM) EBIT $1.38b
Free Cash Flow (TTM) Free Cash Flow $1.08b
Cash position $3.27b
EPS (TTM) EPS $24.60
P/E forward 11.97
P/S forward 4.61
EV/Sales forward 3.66
Short interest 6.06%
Show more

Is United Therapeutics Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

United Therapeutics Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a United Therapeutics Corporation forecast:

7x Buy
50%
6x Hold
43%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a United Therapeutics Corporation forecast:

Buy
50%
Hold
43%
Sell
7%

Financial data from United Therapeutics Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,877 2,877
24% 24%
100%
- Direct Costs 310 310
20% 20%
11%
2,568 2,568
24% 24%
89%
- Selling and Administrative Expenses 637 637
50% 50%
22%
- Research and Development Expense 481 481
18% 18%
17%
1,450 1,450
17% 17%
50%
- Depreciation and Amortization 73 73
36% 36%
3%
EBIT (Operating Income) EBIT 1,377 1,377
16% 16%
48%
Net Profit 1,195 1,195
21% 21%
42%

In millions USD.

Don't miss a Thing! We will send you all news about United Therapeutics Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

United Therapeutics Corporation Stock News

Neutral
Seeking Alpha
2 days ago
Start Time: 09:00 January 1, 0000 9:31 AM ET United Therapeutics Corporation (NASDAQ:UTHR ) Q4 2024 Earnings Conference Call February 26, 2025, 09:00 AM ET Company Participants Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO James Edgemond - CFO and Treasurer Leigh Peterson - EVP, Product Development and Xenotransplantation Pat Poisson - EVP, Technical Operations D...
Neutral
Business Wire
2 days ago
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. “I want to congratulate every Unitherian for their relentless dedication, ...
Positive
Seeking Alpha
3 days ago
United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by Tyvaso (+33% YoY), and maintains high margins and low debt burden, with a 39% growth potential. Key growth drivers include Tyvaso's expansion into IPF, Ralinepag development, xenotransplantation breakth...
More United Therapeutics Corporation News

Company Profile

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Head office United States
CEO Martine Rothblatt
Employees 1,305
Founded 1996
Website www.unither.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today